Beam Therapeutics (BEAM) EBT Margin (2019 - 2026)
Beam Therapeutics (BEAM) reported EBT Margin of 306.72% for Q1 2026, up 115810.0% year-over-year from N/an in Q1 2025, and down 243.27% quarter-over-quarter from 214.09% in Q4 2025.
Beam Therapeutics (BEAM) EBT Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of EBT Margin data on file, last reported at 306.72% in Q1 2026.
- EBT Margin for Q1 2026 came in at 306.72%, up 115810.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 41.5% (up 56792.0% YoY), and the FY2025 annual result was 57.24%, up 53582.0% from the prior year.
- EBT Margin declined to 306.72% in Q1 2026 per BEAM's latest filing, from 214.09% in the prior quarter.
- Over five years, EBT Margin peaked at 214.09% in Q4 2025 and troughed at 1464.82% in Q1 2025.
- A 5-year average of 605.67% and a median of 516.9% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2024: EBT Margin surged 333900364 bps in 2022, then tumbled 87787 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 186.4% in 2022, then jumped by 124 bps to 45.59% in 2023, then slumped by 759 bps to 300.51% in 2024, then jumped by 171 bps to 214.09% in 2025, then plunged by 243 bps to 306.72% in 2026.
- Business Quant data shows BEAM's EBT Margin at 306.72% in Q1 2026, 214.09% in Q4 2025, and 1162.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -306.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -306.72% |
| Dec 31, 2025 | 214.09% |
| Sep 30, 2025 | -1,162.38% |
| Jun 30, 2025 | -1,208.26% |
| Mar 31, 2025 | -1,464.82% |
| Dec 31, 2024 | -300.51% |
| Sep 30, 2024 | -677.47% |
| Jun 30, 2024 | -773.12% |
| Mar 31, 2024 | -1,245.38% |
| Dec 31, 2023 | 45.59% |
| Sep 30, 2023 | -558.88% |
| Jun 30, 2023 | -411.49% |
| Mar 31, 2023 | -367.51% |
| Dec 31, 2022 | -186.40% |
| Sep 30, 2022 | -516.90% |
| Jun 30, 2022 | -479.86% |
| Mar 31, 2022 | -896.36% |
| Dec 31, 2021 | -126.71% |
| Sep 30, 2021 | -3,685.19% |
| Jun 30, 2021 | -983,766.67% |